

FluoGuide Q&A sessions highlight partnerships accelerating FG001 commercialization

Copenhagen, Denmark, 10 August 2025 – FluoGuide A/S is releasing a summary of its live-recorded interview at Redeye (English) on 8 August 2025 and its live Q&A session hosted by FluoGuide (Danish) on 8 August 2025. Both focused on the company's partner-driven strategy to accelerate the commercialization of FG001 and expand its market potential.

Collaborations with industry leaders regarding FluoGuide's lead product in fluorescence-guided surgery – FG001:

- Intuitive Surgical
- Olympus
- SurgVision (part of the Bracco Group)

The partners bring global technology leadership, market reach, and strong validation of FG001's potential. An additional 1–2 partnerships are expected to be formalized during 2025–26, further reinforcing this momentum.

These non-exclusive agreements aim to integrate FG001 seamlessly into leading surgical platforms, reducing regulatory and clinical risk, enabling faster adoption, and expanding the product's potential across multiple cancer indications.

In the short term, FluoGuide's focus is on building strong collaborative relationships that prepare the ground for deeper cooperation. Looking ahead, the we aim to:

- Support FG001's market entry through alliances with key surgical platform providers
- Ensure smooth integration and optimization of FG001 in surgical workflows
- De-risk clinical trials and regulatory approvals
- Expand the indications for FG001
- Enhance the combined value proposition of FG001 with advanced surgical equipment

"The focus is clear – we are building a strong foundation for FG001's commercial success, enabling faster, more cost-effective, and broader market penetration," said Morten Albrechtsen, CEO of FluoGuide.

Both recordings are available, [Redeye](#) (English) and Q&A session hosted by [FluoGuide](#) (Danish).

For further information, please contact:

Morten Albrechtsen, CEO

FluoGuide A/S

Phone: +45 24 25 62 66

E-mail: ma@fluoguide.com

About FluoGuide

FluoGuide's primary focus is to maximize surgical outcomes in oncology. FluoGuide's lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide's products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, this improved precision enhances the likelihood of achieving a complete cure and helping to lower healthcare costs. FluoGuide has demonstrated that FG001 is both effective and well tolerated in a proof-of-concept phase I/II clinical study in patients with high-grade glioma undergoing surgery. FluoGuide is also exploring FG001 in three other severe cancer indications: lung cancer (phase IIa), head & neck cancer (phase IIa), and both meningioma and low-grade glioma. FluoGuide is listed on Nasdaq First North Sweden under the ticker "FLUO"

For more information, please visit: www.fluoguide.com

Follow FluoGuide on LinkedIn: <https://www.linkedin.com/company/fluoguide/>

Sign up to receive FluoGuide news: <https://fluoguide.com/investor/email-alerts/>

For further information, please contact:

Morten Albrechtsen, CEO

FluoGuide A/S

Phone: +45 24 25 62 66

E-mail: ma@fluoguide.com

About FluoGuide

FluoGuide's primary focus is to maximize surgical outcomes in oncology. FluoGuide's lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide's products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, this improved precision enhances the likelihood of achieving a complete cure and helping to lower healthcare costs. FluoGuide has demonstrated that FG001 is both effective and well tolerated in a proof-of-concept phase I/II clinical study in patients with high-grade glioma undergoing surgery. FluoGuide is also exploring FG001 in three other severe cancer indications: lung cancer (phase IIa), head & neck cancer (phase IIa), and both meningioma and low-grade glioma. FluoGuide is listed on Nasdaq First North Sweden under the ticker "FLUO".

For more information on FluoGuide's uPAR technology platform and our pipeline please visit our home page www.fluoguide.com

Attachments

[FluoGuide Q&A sessions highlight partnerships accelerating FG001 commercialization](#)